Log in to your Inderes Free account to see all free content on this page.
PILA PHARMA
4.39
SEK
-0.23 %
PILA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-0.23%
+17.07%
+17.07%
-11.85%
-33.89%
+185.06%
-22.09%
-
-49.87%
PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the painful rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.
Read moreMarket cap
119.09M SEK
Turnover
143.76K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
27.2.
2025
Annual report '24
29.4.
2025
General meeting '25
27.8.
2025
Interim report Q2'25
ShowingAll content types
PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio